Key points
- CRISPR comes from a bacterial immune system. Scientists adapted it into a programmable tool for cutting DNA at a chosen location.
- A guide RNA matches the target DNA sequence and directs the Cas9 enzyme to cut there. The cell's own repair processes then change the gene.
- The 2012 paper that showed Cas9 could be programmed this way led to the 2020 Nobel Prize in Chemistry for Emmanuelle Charpentier and Jennifer Doudna.
- Casgevy, approved by the FDA on December 8, 2023 for sickle cell disease, was the first FDA-approved therapy to use CRISPR/Cas9.
- Newer techniques, base editing and prime editing, can change DNA without making a full double-strand break.
CRISPR is a technology that lets scientists change DNA at a precise, chosen location in a living cell. It has transformed biological research in little more than a decade, and it has already produced an approved medicine. Understanding how it works helps explain both its promise and the questions experimental CRISPR drugs still have to answer.
Where CRISPR comes from
CRISPR stands for clustered regularly interspaced short palindromic repeats, a pattern of repeated DNA sequences first noticed in bacteria. It turned out to be part of a bacterial immune system. When a virus infects a bacterium, the bacterium can store a short piece of the virus's DNA in its own genome. If the same virus attacks again, the bacterium uses that stored sequence to recognize the virus and cut its DNA, disabling it.
In 2012, a team led by Emmanuelle Charpentier and Jennifer Doudna showed in Science that this system, built around a protein called Cas9, could be reprogrammed to cut any DNA sequence researchers chose. They received the 2020 Nobel Prize in Chemistry for the discovery. The Nobel committee described the tool as "genetic scissors."
How it works, step by step
1. The guide
Scientists design a short guide RNA whose sequence matches the stretch of DNA they want to edit. In the cell, the guide RNA pairs with the matching DNA sequence like a key fitting a lock.
2. The cut
The guide RNA is bound to the Cas9 enzyme. When the guide finds its matching DNA sequence, Cas9 cuts both strands of the DNA at that spot, making a double-strand break.
3. The repair
Cells repair broken DNA automatically, and the repair is what changes the gene. There are two main routes:
| Repair route | What happens | Typical use |
|---|---|---|
| Non-homologous end joining | The cell glues the broken ends back together, often adding or deleting a few DNA letters | Disabling ("knocking out") a gene |
| Homology-directed repair | The cell copies a supplied template DNA sequence into the break | Correcting a mutation or inserting new DNA |
Disabling a gene is relatively efficient. Precisely correcting a gene is harder, because cells use the template-based repair route less often.
The first approved CRISPR therapy
On December 8, 2023, the FDA approved Casgevy (exagamglogene autotemcel) for sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises, the painful episodes the disease causes. The FDA described it as the first approved therapy to use CRISPR/Cas9.
Casgevy is an ex vivo therapy:
- A patient's blood-forming stem cells are collected.
- The cells are edited in the laboratory with CRISPR/Cas9, so that they produce a form of hemoglobin normally made before birth, which does not sickle.
- The patient receives conditioning chemotherapy to clear space in the bone marrow.
- The edited cells are infused back into the patient, where they take up residence and produce healthier red blood cells.
In vivo editing
The next frontier is in vivo editing, delivering the CRISPR machinery directly into the body, for example to the liver using lipid nanoparticles similar to those used in mRNA vaccines. In vivo editing avoids collecting and processing a patient's cells, but it has to deliver the editing tools to the right tissue, and only that tissue. Several in vivo editing programs are in clinical trials.
Beyond cutting: base and prime editing
Cutting both DNA strands can cause unintended changes at the target site. Two newer approaches, both developed in the laboratory of David Liu, avoid a full double-strand break:
- Base editing (first reported in Nature in 2016) chemically converts one DNA letter into another at the target site. Many disease-causing mutations are single-letter changes, so this can correct them directly.
- Prime editing (first reported in Nature in 2019) uses a modified Cas9 together with a template built into an extended guide RNA to "search and replace" short stretches of DNA.
Risks and open questions
Experimental CRISPR drugs are judged on questions that matter little for conventional drugs:
- Off-target editing. The guide RNA may direct cuts to similar sequences elsewhere in the genome.
- Unintended changes at the target. Repair can produce larger deletions or rearrangements than intended.
- Permanence. Edits to DNA are generally permanent, so long-term follow-up of patients is essential.
- Delivery. Getting the editing machinery into the right cells in the body remains a central technical challenge.
- Immune responses. Cas9 comes from bacteria, and some people have pre-existing immunity to it.
- Cost and access. Ex vivo therapies are complex to manufacture and require intensive treatment at specialized centers.
How CRISPR drugs are reviewed
In the United States, gene-editing therapies are reviewed by the FDA's Center for Biologics Evaluation and Research (CBER) as gene therapies. They must meet the same standard of substantial evidence of effectiveness as any other drug, and the FDA generally requires long-term follow-up studies because of the permanent nature of the changes. For how review works, see How Does the FDA Approve New Drugs?
Sources
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–821.Peer-reviewed
- The Nobel Prize in Chemistry 2020: press release.Industry report
- U.S. Food and Drug Administration. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease (December 8, 2023).Regulator
- Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420–424.Peer-reviewed
- Anzalone AV, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–157.Peer-reviewed
This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.